Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD503 in pediatric anxiety disorders
NCT01470469Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guanfacine in generalized anxiety disorder (GAD), separation anxiety disorder (SAD), Social Anxiety Disorder (SAD), sponsored by Takeda. Started Jan 2012; status: completed.
02
Drugs
guanfacine
03
Conditions
generalized anxiety disorder (GAD)separation anxiety disorder (SAD)Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT01470469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470469.